July 7, 2023

## VIA EDGAR

Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549

Attention: Lauren Hamill

Re: Onconova Therapeutics, Inc. Registration Statement on Form S-3 Filed June 30, 2023 File No. 333-273081

Ladies and Gentlemen:

Pursuant to Rule 461 under the Securities Act of 1933, as amended, Onconova Therapeutics, Inc. (the "Company") hereby requests acceleration of the effective date of the above referenced registration statement, as amended, so that such registration statement may become effective at 4:30 p.m. (Washington, D.C. time) on July 11, 2023, or as soon as practicable thereafter.

## ONCONOVA THERAPEUTICS, INC.

By: /s/ MARK GUERIN

Name: Mark Guerin Title: Chief Operating Officer & Chief Financial Officer